Pam Taub, MD, FACC, FASPC

home / authors / pam-taub-md-facc-faspc

Articles

Use of Non-statin Therapies in Patients With High Coronary Artery Calcium (CAC) Scores

Erin D. Michos, MD, MHS;Pam Taub, MD, FACC, FASPC;Robert Busch, MD;Alison Bailey, MD, FACC;Jorge Plutzky, MD

November 18th 2022

Pam Taub, MD, FACC, FASPC, shares her thoughts on use of coronary artery calcium (CAC) scores when treating patients with nonstatin therapies.

Guideline Recommendations for Lipid Lowering

Erin D. Michos, MD, MHS;Pam Taub, MD, FACC, FASPC;Robert Busch, MD;Alison Bailey, MD, FACC;Jorge Plutzky, MD

November 18th 2022

Drs Erin Michos, Pam Taub, Robert Busch, Alison Bailey, and Jorge Plutzky review guidelines and recommendations for using lipid-lowering agents in addition to statins.

Less Commonly Used Lipid Lowering Agents in Hypercholesterolemia

Erin D. Michos, MD, MHS;Pam Taub, MD, FACC, FASPC;Robert Busch, MD;Alison Bailey, MD, FACC;Jorge Plutzky, MD

November 11th 2022

An expert panel reviews less frequently used lipid-lowering agents in hypercholesterolemia.

Lipid Lowering Agents Beyond Statins: Bempedoic Acid

Erin D. Michos, MD, MHS;Pam Taub, MD, FACC, FASPC;Robert Busch, MD;Alison Bailey, MD, FACC;Jorge Plutzky, MD

November 11th 2022

A panel of experts discusses use of bempedoic acid to manage hypercholesterolemia and data with bempedoic acid in combination with other lipid-lowering agents.

Lipid Lowering Agents Beyond Statins: Ezetimibe and PCSK9 Inhibitors

Erin D. Michos, MD, MHS;Pam Taub, MD, FACC, FASPC;Robert Busch, MD;Alison Bailey, MD, FACC;Jorge Plutzky, MD

November 4th 2022

Drs Erin Michos, Pam Taub, Robert Busch, Alison Bailey, and Jorge Plutzky, discuss use of ezetimibe and PCSK9 targeting agents for lipid lowering.

Use of Statins in Management of Hypercholesterolemia

Erin D. Michos, MD, MHS;Pam Taub, MD, FACC, FASPC;Robert Busch, MD;Alison Bailey, MD, FACC;Jorge Plutzky, MD

November 4th 2022

Drs Erin Michos, Pam Taub, Robert Busch, Alison Bailey, and Jorge Plutzky, discuss use of statins in managing hypercholesterolemia based on varying levels of risk.

Achievement of LDL-C Goals in the Real World

Erin D. Michos, MD, MHS;Pam Taub, MD, FACC, FASPC;Robert Busch, MD;Alison Bailey, MD, FACC;Jorge Plutzky, MD

October 28th 2022

Alison Bailey, MD, FACC, reviews real-word data about LDL-C control and achievement of goals.

Achievement of Goals in ASCVD

Erin D. Michos, MD, MHS;Pam Taub, MD, FACC, FASPC;Robert Busch, MD;Alison Bailey, MD, FACC;Jorge Plutzky, MD

October 28th 2022

A panel of experts discuss the importance of achieving low-density lipoprotein cholesterol (LDL-C) in patients.

Personalized Treatment for Patients with ASCVD

Erin D. Michos, MD, MHS;Pam Taub, MD, FACC, FASPC;Robert Busch, MD;Alison Bailey, MD, FACC;Jorge Plutzky, MD

October 21st 2022

Experts in cardiology share their thoughts on patient/clinician communication and treatment customized to the individual patient.

Impact of Lipid Lowering on Risk for ASCVD

Erin D. Michos, MD, MHS;Pam Taub, MD, FACC, FASPC;Robert Busch, MD;Alison Bailey, MD, FACC;Jorge Plutzky, MD

October 21st 2022

Drs Erin Michos, Pam Taub, Robert Busch, Alison Bailey, and Jorge Plutzky discuss the impact of lipid lowering on the risk of ASCVD.

Risk Enhancing Factors in ASCVD

Erin D. Michos, MD, MHS;Pam Taub, MD, FACC, FASPC;Robert Busch, MD;Alison Bailey, MD, FACC;Jorge Plutzky, MD

October 14th 2022

A panel of experts comments on the importance of risk assessment in ASCVD as well as factors that contribute to risks.

Overview of Atherosclerotic Cardiovascular Diseases (ASCVD) and Hypercholesterolemia

Erin D. Michos, MD, MHS;Pam Taub, MD, FACC, FASPC;Robert Busch, MD;Alison Bailey, MD, FACC;Jorge Plutzky, MD

October 14th 2022

Drs Erin Michos, Pam Taub, Robert Busch, Alison Bailey, and Jorge Plutzky, provide an overview of the prevalence of atherosclerotic cardiovascular diseases (ASCVD) and hypercholesterolemia in the development of ASCVD.

<1 2